Paul Matteis

if you could try to help do some math for us on the call as it relates to the headwind this quarter from selling weeks

I just wanted to clarify on the selling weeks. We have that dynamic at like close to an 11% sequential headwind

can you talk a little bit more about the criteria physicians are using

there are certain physicians who they actually can use the drug without going through a PNT committee. Any metrics there

are you expecting the average insurer to cross manage between Part B and Part D

how are you at least qualitatively right now thinking about synergies and leveraging existing capabilities

How should we think about the commercial implications if these studies are positive